NCT04691154 - A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2021

Primary Completion Date

June 30, 2024

Study Completion Date

July 31, 2025

Conditions

Pulmonary Arterial HypertensionPulmonary Hypertension Due to Lung Diseases

Interventions

COMBINATION_PRODUCT

L606 inhalation suspension

L606 inhalation suspension, twice daily dosing

Trial Locations (5)

UPMC Montefiore, Pittsburgh

Mayo Clinic Jacksonville, Jacksonville

Arizona Pulmonary Specialists, Phoenix

VA Greater Los Angeles Healthcare, Los Angeles

Brigham and Womens Hospital, Boston